Scalper1 News
Biotech Sucampo Pharmaceuticals (SCMP) has had a mostly good year, but it’s preparing for a challenging future. Sucampo has enjoyed strong sales and profit growth over the past four quarters thanks to its constipation drug Amitiza, marketed by partner Takeda. The drug has driven Sucampo stock to a strong IBD Composite Rating of 86 even after the recent drug-stock hammering. But Amitzia is facing competition from Linzess, a fast-growing rival from Scalper1 News
Scalper1 News